Related Experiment Videos
Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C
P Del Monte1, D Bernasconi, V De Conca
1Department of Endocrinology, Ospedali Galliera, Genoa, Italy.
Hormone Research
|January 1, 1995
Summary
Recombinant interferon-alpha therapy for chronic hepatitis C can affect thyroid function, causing reduced free thyroxine (free-T4) levels. However, insulin-like growth factor-I (IGF-I) levels increased, potentially indicating improved liver health.
Area of Science:
- Endocrinology
- Hepatology
- Pharmacology
Background:
- Chronic active hepatitis C is a significant liver disease.
- Recombinant interferon-alpha is a treatment for hepatitis C.
- Interferon therapy can have systemic effects.
Purpose of the Study:
- To evaluate the hormonal profile changes in patients undergoing interferon-alpha therapy.
- To assess the impact of interferon on thyroid function and other endocrine parameters.
- To explore the relationship between hormonal changes and liver disease markers.
Main Methods:
- Hormonal levels (free-T4, free-T3, TSH, thyroglobulin, calcitonin, antibodies, pituitary, adrenal, sex steroids, IGF-I) were measured in 31 patients.
- Measurements were taken before, and at 3 and 6 months during interferon-alpha therapy.
- Statistical analysis was used to determine significant changes and correlations.
Main Results:
- A significant reduction in free-T4 and a lesser decrease in free-T3 were observed.
- Basal TSH remained unchanged, but TRH stimulation response increased.
- IGF-I levels significantly increased, with an inverse correlation to alanine aminotransferase.
Conclusions:
- Interferon-alpha therapy influences thyroid function in patients with chronic hepatitis C.
- Increased IGF-I may suggest improved hepatic function or a direct effect of interferon.
- Further research is needed to elucidate the precise mechanisms of interferon's endocrine effects.